1-甲基-4-苯基-1,2,3,6-四氢吡啶 基本信息
| 中文名称 | 1-甲基-4-苯基-1,2,3,6-四氢吡啶 |
|---|---|
| 中文同义词 | 1-甲基-4-苯基-1,2,3,6-四氢吡啶;哌替啶杂质B |
| 英文名称 | 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE |
| 英文同义词 | MPTP;1,2,3,6-tetrahydro-1-methyl-4-phenyl-pyridin;1,2,3,6-tetrahydro-1-methyl-4-phenylpyridine;1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)ochloride;NSC 139654;1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, free base;Pyridine,1,2,3,6-tetrahydro-1-methyl-4-phenyl-;1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin |
| CAS号 | 28289-54-5 |
| 分子式 | C12H15N |
| 分子量 | 173.25 |
| EINECS号 | 248-939-7 |
| 相关类别 | 杂环化合物;化合物产品;Neurochemicals;Heterocyclic Compounds |
| Mol文件 | 28289-54-5.mol |
| 结构式 |  |
1-甲基-4-苯基-1,2,3,6-四氢吡啶 性质
| 熔点 | aprox. 36°C |
|---|---|
| 沸点 | 128-132 °C12 mm Hg(lit.) |
| 密度 | 1.001±0.06 g/cm3(Predicted) |
| 储存条件 | Inert atmosphere,Room Temperature |
| 溶解度 | 氯仿（微溶）、二氯甲烷（微溶）、乙酸乙酯（微溶） |
| 形态 | 固体 |
| 酸度系数(pKa) | 8.66±0.40(Predicted) |
| 颜色 | 淡黄色至浅黄色 |
| Merck | 13,6319 |
| 稳定性 | 稳定的。与强氧化剂不相容。 |
安全信息
| 危险品标志 | T |
|---|---|
| 危险类别码 | 25-39/23/24/25 |
| 安全说明 | 45 |
| 危险品运输编号 | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS号 | UT8358900 |
| 危险等级 | 6.1(b) |
| 包装类别 | III |
| 毒害物质数据 | 28289-54-5(Hazardous Substances Data) |
| 毒性 | Human toxicity originally discovered when it was an unexpected by-product from the illicit synthesis of a heroin substitute (i.e., meperidine analog). Currently used experimentally as the primary animal model for the study of Parkinson’s disease. MPTP is a neurotoxicant that is activated to 1-methyl-4-phenylpyridinium ion (MPP1) by the actions of monoamine oxidase B located in the mitochondria of brain astrocytes. The MPP1 is then transported into dopamine, and to a lesser extent, other monoaminergic neurons. Once inside these dopamine neurons in the substantia nigra, it destroys these neurons by mechanisms that may involve an oxidative cascade and/or inhibition of electron transport. Intoxication causes a parkinsonism syndrome almost identical in signs and symptoms to Parkinson’s disease, including rigidity, bradykinesia, tremor, and postural instability. In the event of known ingestion, immediate (but not delayed) administration of a monoamine oxidase inhibitor (especially one selective for MAO-B like deprenyl) and dopamine uptake inhibitor can be therapeutic. |
| 提供商 | 语言 |
|---|---|
|
英文
|